Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ± Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection
Brief Summary: This is a study of the safety and efficacy of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) ± ribavirin (RBV). The primary efficacy endpoint will be Sustained Virologic Response 12 weeks after the end of all study therapy (SVR12) in each of the treatment arms.


Options:
A: Arm Label: Sofosbuvir+PEG+RBV; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Sofosbuvir+PEG+RBV | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): Sofosbuvir+PEG+RBV | Intervention Type: DRUG; Name: PEG; Assigned to Arm(s): Sofosbuvir+PEG+RBV
B: Arm Label: A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Placebo to Elbasvir, Drug: Ribavirin | Arm Label: A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Placebo to Elbasvir, Drug: Ribavirin | Arm Label: A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Intervention Type: DRUG; Name: Grazoprevir; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk, B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk, B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk, B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk, D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | Intervention Type: DRUG; Name: Elbasvir; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk, B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk, B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk, B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk, D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | Intervention Type: DRUG; Name: Placebo to Elbasvir; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk, B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk, C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk
C: Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin | Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Placebo for ribavirin | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV, ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Placebo for ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Arm Label: 12 Week Cohort; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Arm Label: 16 Week Cohort; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): 12 Week Cohort, 16 Week Cohort | Intervention Type: DRUG; Name: Pegylated interferon alfa-2a; Assigned to Arm(s): 12 Week Cohort, 16 Week Cohort, Control | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 12 Week Cohort, 16 Week Cohort, Control

Answer: B